Abstract—Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder. With population aging, its incidence rises continuously, imposing a heavy burden on society. Currently, relevant drugs can only alleviate disease progression but cannot achieve a complete cure, which urgently calls for in-depth research on AD pharmacological treatments. This paper conducts a comprehensive review, a gap that urgently necessitates in-depth research into AD pharmacological treatments. It provides an overview of AD and its current treatment landscape, involving the disease’s status, the efficacy evaluation of pharmacotherapies, and the core value and significance of pharmacotherapy in AD intervention. Then, it explores AD’s pathogenesis and pharmacotherapeutic targets. Additionally, the efficacy and safety of AD drug therapies are analyzed. Finally, limitations and challenges in current AD research are discussed. Through this study, it is concluded that although there are some advances in AD pharmacological treatments, there remains a long path to achieving a complete cure, and further exploration of disease mechanisms and innovative drug development is therefore essential.
 
Keywords—Alzheimer’s disease, pharmacotherapeutic targets, pathogenesis, safety risks, individualized treatment

Cite: Xinran Wang, "Current Status, Efficacy Evaluation and Development Prospects of Pharmacological Treatments for Alzheimer’s Disease," International Journal of Pharma Medicine and Biological Sciences, Vol. 15, No. 3, pp. 94-96, 2026.

Copyright © 2026 by the authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).